Company profile NTLA
Intellia Therapeutics Inc
intellia therapeutic’s core mission is to develop curative medicines, utilizing the promise of the crispr/cas9 gene editing technology. the development of crispr/cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. adapted from a natural cellular process, crispr/cas9 permits the editing of any gene in any organism with unpreced...ented simplicity and flexibility. the incredible potential of this technology for treating human genetic disease inspired a group of life science veterans to create intellia therapeutics. intellia was founded in 2014 by caribou biosciences and atlas venture, along with a consortium of scientists who have helped define the space. intellia therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of crispr/cas9 technology for human therapeutic use. intellia has built an experienced team of individuals to meet the challenges of bringing crispr/cas9 therapeutics to the
Show More
After 39 days of this quarter the interest is at 75.0. Based on that we can calculate that during remaining 52 days it will total up to 175.0. esmo expected interest is significantly lower compared to previous quarter (-57.9%) but similar to same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 79 | 174 120.3% QoQ | 392 125.3% QoQ | 164 -58.2% QoQ |
| 2020 | 150 89.9% YoY -8.5% QoQ | 128 -26.4% YoY -14.7% QoQ | 274 -30.1% YoY 114.1% QoQ | 106 -35.4% YoY -61.3% QoQ |
| 2021 | 98 -34.7% YoY -7.5% QoQ | 119 -7.0% YoY 21.4% QoQ | 242 -11.7% YoY 103.4% QoQ | 114 7.5% YoY -52.9% QoQ |
| 2022 | 149 52.0% YoY 30.7% QoQ | 194 63.0% YoY 30.2% QoQ | 440 81.8% YoY 126.8% QoQ | 178 56.1% YoY -59.5% QoQ |
| 2023 | 199 33.6% YoY 11.8% QoQ | 233 20.1% YoY 17.1% QoQ | 279 -36.6% YoY 19.7% QoQ | 416 133.7% YoY 49.1% QoQ |
| 2024 | 75 -62.3% YoY -82.0% QoQ | - | - | - |
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
The average 5 years interest of esmo was 16.1 per week. The last year interest of esmo compared to the last 5 years has changed by 32.92%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 27.15%.
Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
After 39 days of this quarter the interest is at 53.0. Based on that we can calculate that during remaining 52 days it will total up to 124.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 56 | 66 17.9% QoQ | 66 0.0% QoQ | 68 3.0% QoQ |
| 2020 | 68 21.4% YoY 0.0% QoQ | 68 3.0% YoY 0.0% QoQ | 71 7.6% YoY 4.4% QoQ | 76 11.8% YoY 7.0% QoQ |
| 2021 | 103 51.5% YoY 35.5% QoQ | 190 179.4% YoY 84.5% QoQ | 131 84.5% YoY -31.1% QoQ | 117 53.9% YoY -10.7% QoQ |
| 2022 | 171 66.0% YoY 46.2% QoQ | 145 -23.7% YoY -15.2% QoQ | 129 -1.5% YoY -11.0% QoQ | 118 0.9% YoY -8.5% QoQ |
| 2023 | 161 -5.8% YoY 36.4% QoQ | 119 -17.9% YoY -26.1% QoQ | 122 -5.4% YoY 2.5% QoQ | 139 17.8% YoY 13.9% QoQ |
| 2024 | 53 -67.1% YoY -61.9% QoQ | - | - | - |
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
The average 5 years interest of intellia -stock was 8.57 per week. The last year interest of intellia -stock compared to the last 5 years has changed by 17.85%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 83.64%.
Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for NTLA
Earnings date: 2024-02-22 After close
Company name: Intellia Therapeutics Inc
Sector: Manufacturing
Company's websiteHyperchartsYahoo FinanceMarketWatchStockTwitsSEC FilingsSwaggyStocksLatest articles
2026-05-13T18:39:12Z
Analyst Upgrades
Bernstein Maintains Market Perform on Intellia Therapeutics, Raises Price Target to $172026-05-13T11:05:29Z
Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Intellia Therapeutics, Lowers Price Target to $252026-05-12T21:23:43Z
Analyst Upgrades
Canaccord Genuity Maintains Buy on Intellia Therapeutics, Lowers Price Target to $492026-05-12T12:44:09Z
Analyst Upgrades
Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $12 Price Target2026-05-11T11:30:00Z
GlobeNewswire
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates2026-05-05T11:30:00Z
GlobeNewswire
Intellia Therapeutics to Participate in Upcoming Investor Conferences2026-05-01T20:01:00Z
GlobeNewswire
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2026-04-29T11:00:00Z
GlobeNewswire
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock2026-04-28T17:43:09Z
Analyst Upgrades
Canaccord Genuity Maintains Buy on Intellia Therapeutics, Raises Price Target to $582026-04-28T16:07:23Z
Analyst Upgrades
Goldman Sachs Maintains Sell on Intellia Therapeutics, Raises Price Target to $92026-04-28T14:01:04Z
Analyst Upgrades
Citizens Maintains Market Outperform on Intellia Therapeutics, Raises Price Target to $302026-04-28T13:58:45Z
Analyst Upgrades
Morgan Stanley Maintains Equal-Weight on Intellia Therapeutics, Raises Price Target to $152026-04-27T20:01:00Z
GlobeNewswire
Intellia Announces Proposed Public Offering of Common Stock2026-04-27T17:56:32Z
Analyst Upgrades
Chardan Capital Maintains Buy on Intellia Therapeutics, Raises Price Target to $302026-04-27T17:48:46Z
Analyst Upgrades
Baird Maintains Neutral on Intellia Therapeutics, Raises Price Target to $13